Avanir vet Keith Katkin takes charge at Urovant; Teva unloads assets while uploading new CEO

Roivant Sciences has added another seasoned biotech exec to its stable of CEOs. The umbrella group announced this morning that Keith Katkin, the longtime CEO at Avanir up to its sale to Otsuka, is taking the CEO’s job at Urovant. The startup vant is focused on urological conditions.

⇨ Most companies wait for a new CEO to step in before they reorganize, but Teva never had the time. The troubled Israeli biopharma company has sold off the last of its women health assets, raising about $1.4 billion as Kare Schultz prepares to take the helm.

Deciphera $DCPH plans to sell 6.3 million IPO shares at $15 to $17 apiece, looking to raise about $100 million for its development work. Insiders have their eyes on $30 million of that.

Novartis’ Alcon is handing the rights to Jetrea back to Belgium’s ThromboGenics.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,600+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->